A Big Development for Pfizer-BioNTech Covid Vaccine; They Get A Nod From WHO For Emergency Usage

The efficacy of Pfizer-BioNTech covid vaccine has been justified from their trial phase results and now they have got approval from WHO to use the vaccine in emergency conditions.

0
A Big Development for Pfizer-BioNTech Covid Vaccine; They Get A Nod From WHO For Emergency Usage.the policy times

Pfizer-BioNTech has jointly become the first covid vaccine developer who has got the nod from the World Health Organization to give a dose of the vaccine in an emergency condition. They will be administered in two doses, and the authorities will look after the fact that poor countries do not get delayed doses due to the non-availability of proper resources.

Britain on inoculation drive

Back on December 8, Britain started its inoculation drive of the covid vaccine after which other countries like Europe, Canada, and the US also followed the same drive. “This is a very positive step towards ensuring global access to Covid-19 vaccines. But I want to emphasize the need for an even greater global effort to achieve enough vaccine supply to meet the needs of priority populations everywhere”, said a WHO official after the first such validation of covid vaccine was granted.

Regional partners active on import/export function

As soon as the validation came into action, several governing authorities started operations to ensure that the poor countries get the benefits of the vaccine at the earliest. They have also called for action that the import and export of the vaccine must be done rapidly to reach people globally. An initiative is being made by CEPI, the GAVI vaccine alliance, and the UN health agency to launch COVAX under which they will try to reach out to the proper countries for providing the vaccine on time.

Also read: India Sees Hope; Covid Vaccine Likely To Be Available By 2021

“Safety, efficacy and quality” tested before the nod

Apart from the quality checks done on various levels, the vaccine has also been under scrutiny for several trial phases after which it got the nod of the World Health Organization. “The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO and that the benefits of using the vaccine to address Covid-19 offset potential risks”, said WHO in its official statement. We can only hope that it not only works for covid affected people worldwide in emergency conditions but also reaches them at the right time. A delayed vaccination may lead to more troubles than expected.

The Policy Times suggestion

  • It is good news for the entire world that finally a vaccine got its nod for implementation in emergency conditions. But the concerned authorities must also look out for any possibility of side effects as the vaccine would be implemented to emergency patients who may develop any negative impact as well.
  • Also, if the vaccine is administered to the emergency patient then the cost must also be very affordable so that people do not have to think twice before going for a dose of the vaccine.
  • The initiative to reach out to a majority of countries is also a good move that must be appreciated. Like this, more people in need can be administered the vaccine.

Also read: Hopes Shatter as Covid Vaccine Pfizer’s Trial Volunteers Develop Bell’s Palsy

Summary
Article Name
A Big Development for Pfizer-BioNTech Covid Vaccine; They Get A Nod From WHO For Emergency Usage
Description
The efficacy of Pfizer-BioNTech covid vaccine has been justified from their trial phase results and now they have got approval from WHO to use the vaccine in emergency conditions.
Author
Publisher Name
THE POLICY TIMES
Publisher Logo